Clinical Edge Journal Scan

High red and processed meat intake tied with screen-detected colorectal lesions


 

Key clinical point: A significant association was observed between high intake of red and processed meat and the presence of advanced colorectal lesions at colonoscopy in fecal occult blood test (FIT)-positive participants.

Major finding: Each 100 g/day increase in the intake of red and processed meat increased the risk for advanced colorectal lesion by 32% (odds ratio [OR] 1.32; 95% CI 1.09-1.60). The risk was prominent among patients with high vs low (≥100 vs <50 g/day) absolute intake of processed meat (OR 1.19; 95% CI 1.09-1.31).

Study details : This study evaluated associations between red and processed meat intake and screen-detected colorectal lesions in 1162 FIT-positive participants from the Norwegian CRCbiome study.

Disclosures: This study was supported by the Norwegian Cancer Society, the Research Council of Norway, and the South Eastern Norway Regional Health Authority . No competing interests were declared.

Source: Kværner AS et al. Associations of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr. 2022 (Sep 7). Doi: 10.1017/S0007114522002860

Recommended Reading

Inhibiting adenosine pathways may be key to CRC treatment
MDedge Hematology and Oncology
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
MDedge Hematology and Oncology
‘Unprecedented’ responses to neoadjuvant treatment in dMMR colon cancer
MDedge Hematology and Oncology
Annual screening benefits people at high-risk for pancreatic cancer
MDedge Hematology and Oncology
Time to cancer diagnoses in U.S. averages 5 months
MDedge Hematology and Oncology
Early rectal cancer: Neoadjuvant chemotherapy may reduce need for invasive surgeries
MDedge Hematology and Oncology
Stage II/III rectal cancer: Shift in treatment pattern and outcomes
MDedge Hematology and Oncology
BRAFV600E mCRC: No survival benefit of FOLFOXIRI+anti-VEGF over doublet+anti-VEGF
MDedge Hematology and Oncology
Distinctly different Acq-GAs profile with upfront anti-EGFR therapy and anti-EGFR-antibody therapy in later lines
MDedge Hematology and Oncology
Evidence supporting use of FIT at a threshold ≥10 μg/g in low-risk population
MDedge Hematology and Oncology